H. Lee Moffitt Cancer Center & Research Institute

SEPTEMBER/OCTOBER

Vol 10, No 5 CME Pretest

In this issue, myeloma and other topics are addressed. First, answer the pretest questions below to assess initial expertise. After reading the articles, proceed with answering the CME posttest questions.

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

  • appreciate the newer approaches to management of multiple myeloma,
  • apply this knowledge in prescribing optimal care for patients with myeloma,
  • discuss the use of gefitinib in lung cancer,
  • utilize the 2003 changes of the AJCC staging system for breast cancer,
  • recognize the importance of first-cycle neutropenic fever in patients with non-Hodgkin’s lymphoma, and
  • manage Fusarium infections.

This program was planned in accordance with ACCME Essentials.

Release Date: September 1, 2003
Expiration Date: September 1, 2004


Pretest

1. What proportion of patients with multiple myeloma are cured using treatment with pulse dexa­methasone-containing regimens (eg, VAD) followed by myeloablative therapy with autologous stem cell support early in the disease?

a. 0%
b. 10% - 15%
c. 20% - 30%
d. 40% - 60%

2. What response rate was reported in a phase II trial of bortezomib in patients with previously treated multiple myeloma?

a. 84%
b. 67%
c. 44%
d. 35%

3. Based on the 6th edition (2003) of the AJCC staging manual, the finding of a single focus of metastatic breast cancer demonstrated only by IHC staining that measured 0.25 mm in a resected axillary node would result in the node as being staged as:

a. N0
b. pN1mi
c. pN1(a)
d. pN1mi(i+)




© Copyright 1996 - 2009 H. Lee Moffitt Cancer Center & Research Institute